Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395058 | 0.98 | PDK1 (0.39) | PDK1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL11802868 | 0.93 | — | — | |
| Glycidol SCHEMBL29249394 | 0.86 | ALDH1A1 (0.40) | PDK1ALDH1A1 | |
| Glycidol SCHEMBL9717914 | 0.86 | ALDH1A1 (0.40) | PDK1ALDH1A1 | |
| SCHEMBL29416339 | 0.86 | CHRM2 (0.33) | PDK1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL1564755 | 0.83 | — | — | |
| SCHEMBL147417 | 0.83 | — | — | |
| Tetrahydrofuran SCHEMBL6278435 | 0.83 | ALDH1A1 (0.42) | PDK1ALDH1A1 | |
| SCHEMBL1032884 | 0.83 | — | — | |
| SCHEMBL895933 | 0.81 | CHRM2 (0.48) | PDK1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047560-A1 | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-02-17 | — | — | US | claimed |
| EP-3849527-A1 | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2021-07-21 | — | — | EP | claimed |
| WO-2020052643-A1 | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (CN) | 2020-03-19 | — | — | WO | claimed |
| US-20140314815-A1 | ADHESIVE SOLID GEL-FORMING FORMULATIONS FOR DERMAL DRUG DELIVERY | NUVO RESEARCH INC. (CA) | 2014-10-23 | — | — | US | claimed |
| WO-2009017767-A2 | COMPOSITIONS AND METHODS FOR DERMALLY TREATING NEUROPATHY WITH MINOXIDIL | ZARS PHARMA, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1968541-A2 | COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | Zars, Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| EP-1959930-A2 | FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | Zars, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1959929-A2 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | Zars, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1959928-A2 | SPRAY-ON FORMULATIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | Zars, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1959931-A2 | COMPOSITIONS AND METHODS FOR DERMALLY TREATING PAIN | Zars, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070196325-A1 | Compositions and methods for dermally treating infections | NUVO RESEARCH INC. (CA) | 2007-08-23 | — | — | US | claimed |
| US-20070196458-A1 | Compositions and methods for dermally treating neuropathic pain | NUVO RESEARCH INC. (CA) | 2007-08-23 | — | — | US | claimed |
| US-20070189980-A1 | Compositions and methods for treating alopecia | ZARS, INC. | 2007-08-16 | — | — | US | claimed |
| US-20070189977-A1 | Spray-on formulations and methods for dermal delivery of drugs | ZARS, INC. | 2007-08-16 | — | — | US | claimed |
| US-20070190124-A1 | Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs | NUVO RESEARCH INC. (CA) | 2007-08-16 | — | — | US | claimed |
| US-20070189978-A1 | Compositions and methods for dermally treating musculoskeletal pain | ZARS, INC. | 2007-08-16 | — | — | US | claimed |
| WO-2007070643-A2 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070679-A2 | COMPOSITIONS AND METHODS FOR DERMALLY TREATING PAIN | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070694-A2 | SPRAY-ON FORMULATIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070695-A2 | FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047560-A1 | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | RIMKLA, TST, PSEN1 | PDK1 1109/4885CHRM2 245/4885CHRM4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.